{
    "organizations": [],
    "uuid": "92dbb581cc621460ba2c2b35e8a7b5fbb1a7d19c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunovia-approved-for-listing-on/brief-immunovia-approved-for-listing-on-nasdaq-stockholm-idUSFWN1R808V",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunovia Approved For Listing On Nasdaq Stockholm",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - IMMUNOVIA AB (PUBL):\n* IMMUNOVIA HAS BEEN APPROVED FOR LISTING ON NASDAQ STOCKHOLM\n* ‍FIRST DAY OF TRADING ON NASDAQ STOCKHOLM IS SCHEDULED FOR 3 APRIL 2018​\n* ‍LAST DAY OF TRADING ON NASDAQ FIRST NORTH IS SCHEDULED FOR 29 MARCH 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-26T15:35:00.000+03:00",
    "crawled": "2018-03-27T11:48:32.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "immunovia",
        "ab",
        "publ",
        "immunovia",
        "approved",
        "listing",
        "nasdaq",
        "stockholm",
        "day",
        "trading",
        "nasdaq",
        "stockholm",
        "scheduled",
        "april",
        "day",
        "trading",
        "nasdaq",
        "first",
        "north",
        "scheduled",
        "march",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}